Company Overview and News

2
Top Ranked Growth Stocks to Buy for June 22nd

2018-06-22 zacks
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, June 22nd:
IP INPAP XCRA

0
Why International Paper Company (IP) Could Be a Top Value Stock Pick

2018-06-22 zacks
Value investing is always a very popular strategy, and for good reason. After all, who doesn’t want to find stocks that have low PEs, solid outlooks, and decent dividends? Fortunately for investors looking for this combination, we have identified a strong candidate which may be an impressive value; International Paper Company (IP - Free Report) . International Paper Company in Focus IP may be an interesting play thanks to its forward PE of 10.
IP INPAP

12
Echo Logistics (ECHO) and ArcBest (ARCB) Are Aggressive Growth Stocks

2018-06-21 zacks
Brian Bolan is our aggressive growth stock strategist here at Zacks Investment Research and he has two more names for your radar screen. The trucking sector has been hot lately and Brian gives us two more stocks in this space. The first is one that he recommended sometime back and was even a portfolio holding in Home Run Investor, a subscriber service that gives buy and sell alerts for growth stocks.
IP MS.PRI MS.PRK INPAP MS.PRE MS.PRF MS.PRG MS MS.PRA

32
CRISPR Science and Stocks: Knowing Enough to Invest

2018-06-20 zacks
By far the most exciting real-time revolution unfolding in Biotechnology is CRISPR gene editing. And the past few months have provided plenty of excitement for Biotech investors as the three public companies who are pure-play manifestations of the technology have made some dramatic moves -- on good news and bad.
NTLA EDIT IP GILD INPAP CRSP

57
General Electric loses place in Dow Jones stock index

2018-06-20 thehindubusinessline
A decade and a half ago GE was the world’s most valuable public company. File Photo - Reuters
GEC GE XOM INPAP WBA IP GM.WS.A GM.WS.B GM.WS.C GNE MSFT GM GM.WSB

64
General Electric loses place in elite Dow Jones Industrial Average for the first time in 100 years

2018-06-20 moneycontrol
General Electric Co has lost its spot in the Dow Jones Industrial Average after over a century in the blue-chip stock index, a new blow to a company that once towered over the American business landscape but is now struggling to retain its standing as an industrial powerhouse.
GEC GE XOM IBN INPAP WBA ICICIBANK IP GM.WS.A 532174 GM.WS.B GM.WS.C GNE MSFT GM GM.WSB

64
General Electric loses place in elite Dow Jones Industrial Average

2018-06-20 moneycontrol
General Electric Co has lost its spot in the Dow Jones Industrial Average after over a century in the blue-chip stock index, a new blow to a company that once towered over the American business landscape but is now struggling to retain its standing as an industrial powerhouse.
GEC GE XOM IBN INPAP WBA ICICIBANK IP GM.WS.A 532174 GM.WS.B GM.WS.C GNE MSFT GM GM.WSB

16
Flash - General Electric dropped from Dow Jones stock index - France 24

2018-06-20 france24
Slumping US industrial giant General Electric will be booted from the prestigious Dow Jones stock index, S&P Dow Jones Indices announced Tuesday.
GEC GE IP INPAP WBA GNE

57
General Electric loses place in elite Dow Jones Industrial Average

2018-06-20 channelnewsasia
Walgreens Boots Alliance Inc will replace General Electric Co in the Dow Jones Industrial Average from June 26, S&P Dow Jones Indices said https://bit.ly/2K4IoSE on Tuesday.
GEC GE XOM INPAP WBA IP GM.WS.A GM.WS.B GM.WS.C GNE MSFT GM GM.WSB

16
General Electric dropped from Dow Jones stock index

2018-06-19 yahoo
New York (AFP) - Slumping US industrial giant General Electric will be booted from the prestigious Dow Jones stock index, S&P Dow Jones Indices announced Tuesday.
GEC GE IP INPAP WBA GNE

16
General Electric dropped from Dow Jones stock index

2018-06-19 channelnewsasia
NEW YORK: Slumping US industrial giant General Electric will be booted from the prestigious Dow Jones stock index, S&P Dow Jones Indices announced on Tuesday (Jun 19).
GEC GE IP INPAP WBA GNE

27
Top Stock Picks for the Week of June 18, 2018

2018-06-18 zacks
Occidental Petroleum (OXY - Free Report) is a large cap E&P which also has a chemical business. While it’s considered a more conservative play on the crude rebound because of its size, investors also get solid management and a dividend still yielding 3.7% even though the stock has rebounded off the 2017 lows. This Zacks Rank #1 (Strong Buy) is expected to see earnings jump an incredible 389% in 2018 as crude prices rise.
HD IP INPAP CRSP ZBRA OXY

117
Top Analyst Upgrades and Downgrades: BlackRock, Chevron, Disney, Intel, Kinder Morgan, Zillow and More

2018-06-18 247wallst
The futures traded lower again Monday morning as we look to see some follow-through selling in the wake of the announcement on the tariffs starting on some overseas products in early July. Investors should be heartened by the outstanding economic news that continues to pour in, and with only two weeks left in the second quarter, it’s a solid bet that earnings will be very positive.
RF.PRB RF.PRA DB KMI.WS INPAP RF BLK IP KMI.PRA KMI CVX GPN TRI CB INTC KMR CVB KMRFZ DIS

17
Growth & Income Buys | Johnson & Johnson and International Paper

2018-06-14 zacks
This week’s video covers two companies where management has made key decisions for the future of their respective companies; Johnson & Johnson (JNJ - Free Report) , and International Paper (IP - Free Report) .
IP FTV JNJ INPAP ZBRA YY

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

CUSIP: 460146903